非均匀性脂肪肝患者腹部超声表现和血脂变化特点*

doi:10.3969/j.issn.1672-5069.2020.01.013

摘要/Abstract

摘要： 目的分析非均匀性脂肪肝患者肝脏超声和血生化指标变化特点。方法 2016年1月～2018年12月我院诊断的非酒精性非均匀性脂肪肝患者90例和同期在我院体检的健康者30例,均行超声检查和血生化指标检测。结果在90例患者中,I型(局部浸润型) 23例(25.6%),II型(叶段浸润型)29例(32.2%),III型(弥漫性非均匀浸润型)38例(42.2%);II型组血清转铁蛋白(SF)为(254.2±98.7)μg/L,显著高于健康人【(175.1±98.4)μg/L,P<0.05】,III型组血清空腹血糖水平为(6.37±0.79)mmol/L,显著高于健康人【(4.85±0.53)mmol/L,P<0.05】,糖化血红蛋白水平为(6.94±0.81)%,显著高于健康人【(4.73±0.57)%,P<0.05】,尿酸水平为(418.3±40.5)μmol/L,显著高于健康人【(354.2±37.8)μmol/L,P<0.05】,SF为(287.3±105.1)μg/L,显著高于健康人【(175.1±98.4)μg/L,P<0.05】;II型血清谷草转氨酶(AST)水平为(51.5±13.4)IU/L,显著高于健康人【(24.2±9.3)IU/L,P<0.05】,谷胺酰转肽酶(GGT)水平为(59.3±31.2)IU/L,显著高于健康人【(29.8±10.1)IU/L,P<0.05】,III型组血清胆固醇水平为(4.7±0.8)mmol/L,显著高于健康人【(3.8±0.6)mmol/L,P<0.05】,甘油三酯水平为(3.2±1.5)mmol/L,显著高于健康人【(1.4±0.3)mmol/L,P<0.05】,AST为(60.2±18.7)IU/L,显著高于健康人【(24.2±9.3)IU/L,P<0.05】,谷丙转氨酶水平为(54.2±29.8)IU/L,显著高于健康人【(30.2±13.4)IU/L,P<0.05】,GGT为(59.3±31.2)IU/L,显著高于健康人【(29.8±10.1)IU/L,P<0.05】。结论超声检查非均匀性脂肪肝诊断准确,能鉴别出轻度脂肪浸润或局限性的脂肪浸润肝组织,结合血生化指标检测,能为脂肪肝的临床诊断提供参考依据。

关键词: 非酒精性脂肪性肝病, 非均匀性脂肪肝, 超声检查, 血生化指标, 诊断

Abstract: Objective The aim of this study was to summarize the ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver (NAHFL). Methods 90 patients with NAHFL and 30 healthy persons were enrolled in our hospital between January 2016 and December 2018, and ultrasonography and blood biochemical indicators were carried out. Results Out of the 90 patients with NAHFL, 23 cases (25.6%) belonged to type I (local invasive type), 29 cases (32.2%) belonged to type II (segmental infiltration type) and 38 cases (42.2%) belonged to type III (diffuse heterogeneous infiltration) type); serum transferrin (SF) level in patients with type II fatty liver was (254.2±98.7) μg/L, significantly higher than [(175.1±98.4) μg/L, P<0.05] in healthy control; the fasting blood glucose level in patients with type III fatty liver was (6.37±0.79) mmol/L, significantly higher P<0.05] in the control, and HbA1c was than in the control, blood uric acid level was (418.3±40.5)μmol/L, significantly higher than in the control, and SF was (287.3±105.1) mg/l, significantly higher than in the control; serum AST level in patients with type II fatty liver was (51.5±13.4) IU/L, significantly higher than in the control, serum GGT level was (59.3±31.2) IU/L, significantly higher than in the control, blood TC in patients with type III fatty liver was (4.7±0.8) mmol/L, significantly higher than in the control, blood TG was (3.2±1.5) mmol/L, significantly higher than in the control, serum AST was (60.2±18.7) IU/L, significantly higher than , serum ALT was (54.2±29.8) IU/L, significantly higher than , and serum GGT level was (59.3±31.2) IU / L, significantly higher than in the control. Conclusion Ultrasonography might show a characteristic features in patients with NAHFL, and the diagnosis might be made at the base of blood analysis in clinical practice.

Key words: Non-alcoholic fatty liver diseases, Heterogeneous fatty liver, Sonography, Biochemical indicators, Diagnosis

柳健, 朱峰发, 唐娟. 非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*[J]. 实用肝脏病杂志, 2020, 23(1): 42-45.

Liu Jian, Zhu Fengfa, Tang Juan. Ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver[J]. Journal of Practical Hepatology, 2020, 23(1): 42-45.

参考文献

[1] von Volkmann H L, Havre R F, Løberg E M, et al. Quantitative measurement of ultrasound attenuation and hepato-renal Index in non-alcoholic fatty liver Disease. Med Ultrason, 2013, 15(1):16.
[2]Lin S C, Heba E, Wolfson T, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol, 2015, 13(7):1337-1345.
[3]邱建民,欧阳蕴瑜,李盈盈,等.超声密度定量分析技术在均匀性脂肪肝的诊断价值.医学影像学杂志,2016,26(11):2020-2022.
[4]Bril F, Ortizlopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int, 2015, 35(9):2139-2146.
[5]Cheah W L, Lee P Y, Chang C T, et al. Prevalence of ultrasound diagnosed nonalcoholic fatty liver disease among rural indigenous community of Sarawak and its association with biochemical and anthropometric measures. Southeast Asian J Trop Med Public Health, 2013, 44(2):309-317.
[6]Khov N, Sharma A, Riley T R. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol, 2014, 20(22):6821.
[7]Kanayama Y, Kamiyama N, Maruyama K, et al. Real-time ultrasound attenuation imaging of diffuse fatty liver disease. Ultrasound Med Biol, 2013, 39(4):692-705.
[8]邢敏,杨自力.血脂、血糖、肝功能等生化指标联合超声诊断脂肪肝及评估其预后的价值.肝脏,2016,21(4):327-328.
[9]Noureddin M, Khoyilar C, Palmer S L. MRI, CT scan, and ultrasound in the diagnosis of nonalcoholic fatty liver disease. J Clin Gastroenterol, 2015, 49(4):351-352.
[10] 邓高峰, 王亚平, 杨笑芳. 某部新兵脂肪肝患病率调查及B超检测的意义. 实用肝脏病杂志, 2016,19(1):88-89.
[11] Petrick A, Benotti P, Wood G C, et al. Utility of ultrasound, transaminases, and visual inspection to assess nonalcoholic fatty liver disease in bariatric surgery patients. Obes Surg, 2015, 25(12):2368-2375.
[12] Akcam M, Boyaci A, Pirgon O, et al. Importance of the liver ultrasound scores in pubertal obese children with nonalcoholic fatty liver disease. Clin Imaging, 2013, 37(3):504-508.
[13] Del M B, Polimeni L, Carnevale R, et al. NOX<sub>2</sub>-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 2014, 14(1):1-8.
[14] Chiloiro M, Caruso M G, Cisternino A M, et al. Ultrasound evaluation and correlates of fatty liver disease: A population study in a mediterranean area. Metab Syndr Relat Disord, 2013, 11(5):349-358.
[15] Onitsuka Y, Takeshima F, Ichikawa T, et al. Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes. Intern Med, 2014, 53(6):545-553.
[16] Vitturi N, Soattin M, De S F, et al. Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord, 2015, 20(2):241-247.
[17] Subramanya M B, Kumar V, Mukherjee S, et al. A CAD system for B-mode fatty liver ultrasound images using texture features. J Med Eng Technol, 2015, 39(2):123-130.
[18] Berzigotti A. Non-invasive assessment of non-alcoholic fatty liver disease: ultrasound and transient elastography. Rev Recent Clin Trials, 2014, 9(3):170-7.
[19] Goulart A C, Oliveira I R, Alencar A P, et al. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian longitudinal study of adult health. Sao Paulo Med J, 2015, 133(2):115-124.
[20] Ma H Y, Zhou Z, Wu S, et al. A computer-aided diagnosis scheme for detection of fatty liver In vivo based on ultrasound kurtosis imaging. J Med Syst, 2016, 40(1):1-9.

非均匀性脂肪肝患者腹部超声表现和血脂变化特点^*

Ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨可芷, 陆伟, 黄丹, 李秀芬, 王雁冰, 周新兰, 丁蓉蓉, 张占卿. γ-谷氨酰转肽酶/胆碱酯酶比值预测慢性乙型肝炎患者肝纤维化程度的效能评价^*[J]. 实用肝脏病杂志, 2020, 23(1): 14-17.
[2]	叶细容, 吕志红, 江峰, 解育新. 两种超声弹性成像技术诊断慢性乙型肝炎患者肝纤维化价值比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 18-21.
[3]	陈丽丽, 符茂雄, 蒙绪标, 方其超. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 38-41.
[4]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.
[5]	毛重山, 殷辉, 肖二辉, 张英英. 非诺贝特对非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 50-53.
[6]	王晶晶, 李春涛, 周卫真. 失代偿期乙型肝炎肝硬化患者尿液视黄醇结合蛋白水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 74-77.
[7]	刘潇, 何年安, 叶显俊, 刘力, 付文学, 陈姣姣. 超声造影对肝细胞癌与肝转移癌的鉴别诊断价值分析[J]. 实用肝脏病杂志, 2020, 23(1): 94-97.
[8]	石莹莹, 王元喜. 应用肝脏影像报告与数据管理系统诊断肝细胞癌的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 98-101.
[9]	高莉, 高屹, 尹秋萍. CT灌注成像联合彩色多普勒超声造影辨别肝脏结节性病变性质临床价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 106-109.
[10]	王秀清, 马燕君, 詹晋莉. 微泡性多囊肝影像学检查表现比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 114-117.
[11]	骆庆玲, 周永健, 唐文娟, 首第文, 黄红丽, 徐豪明, 黄惠康, 何杰, 杜艳蕾, 阮焕梅, 陈慧婷, 曹创裕. 移植NAFLD患者和健康人粪菌对高脂饮食大鼠肠道菌群的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 134-137.
[12]	郭化磊, 卜理琳, 裴颖, 殷宏振, 黄峰. 化浊通瘀汤干预非酒精性脂肪性肝病大鼠血清肿瘤坏死因子-α和瘦素的变化^*[J]. 实用肝脏病杂志, 2020, 23(1): 138-141.
[13]	王纯, 陈东风. Fitz-Hugh-Curtis综合征研究进展^*[J]. 实用肝脏病杂志, 2020, 23(1): 149-152.
[14]	陈慧婷, 周永健. 妊娠期肝内胆汁淤积症诊断与管理[J]. 实用肝脏病杂志, 2020, 23(1): 153-155.
[15]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.